




hoosier oncology group

Annual Report 2012





Letter from the Chairman

Rafat Abonour, M.D.

The Hoosier Oncology Group (HOG) continues its transformation to meet 21st century oncology demands. Today we witness advances in understanding the biology of the cancers we treat and the explosion of new biomarkers and small molecules. The practice of oncology is also changing to deal with the growing number of patients and the costs involved in caring for these patients. In the past year, the Hoosier Oncology Group focused on meeting these challenges.

First, we are grateful for the new Executive Director, Cynthia Burkhardt, as she stepped in to lead our organization into 21st century clinical research. She brings a deep understanding of today's challenges. Her early days in clinical research, caring for patients and working with principal investigators and sponsors, provide the depth and wisdom to understand the anatomy of clinical research. Her passion for clinical research that facilitates personalized cancer treatment is remarkable.

Hoosier Oncology Group is strengthening its relationship with many partners and exploring new collaborations while maintaining our independence and adherence to scientific rigors. As health care is now being concentrated within large organizations, we are working closely with Indiana University Health, the Indiana University Melvin and Bren Simon Cancer Center, to streamline clinical trial design and execution. We are striving to provide access to novel clinical trials and to manage those trials efficiently, with a significant reduction in redundancies and delays.

We are focusing our efforts on personalized medicine because of the promise of better therapy with fewer side effects. We are working closely with a team of researchers leading a revolutionary personalized medicine study designed to increase the cure rate of triple negative breast cancer. To increase the numbers of such trials, we are excited about a new collaboration taking place among the cancer centers of the Big Ten universities. Hoosier Oncology will be coordinating the efforts of this consortium to bring science from the bench to the bedside in record time. Finally, through a grant from the National Cancer Institute, we are working to build an enhanced network to increase the visibility and participation of minority populations in clinical research.

I am delighted with the commitment of the Hoosier Oncology staff to see us through this transformation. We will deliver novel therapies and clinical trial designs throughout Indiana and beyond because we are committed to reduce the incidence of cancer and to increase the number of patients cured from this monster called cancer.

With kind regards,





Letter from Chief Medical Officer

Noah M. Hahn, MD

One of my responsibilities as Chief Scientific Officer for the Hoosier Oncology Group is to develop a sustainable business model for research development and funding. The complexity of clinical and translational cancer research, coupled with inadequate and uncertain research funding, demands a new approach to research collaborations.

I am pleased to introduce the *Big Ten Cancer Research Consortium (BTCRC)*, a new collaboration among leading NCI-designated cancer centers throughout the Midwest. Membership will be made available to Indiana University, University of Illinois, University of Iowa, University of Michigan, University of Minnesota, University of Nebraska, Northwestern University, Penn State University, Purdue University and University of Wisconsin.

The Big Ten Cancer Research Consortium will provide patients and physicians in the Midwest with a more convenient and robust portfolio of treatment options than what currently exists at any singular cancer center. By working together, these member institutions open the door for more efficient science-driven research and more rapid translation to the community.

The conduct of clinical trials within the Big Ten Cancer Research Consortium requires a centralized clinical research infrastructure which is facile in multi-institutional and community-based research. The consortium will conduct highly translational trials with an emphasis on coupling assessment of therapeutic efficacy with development and validation of novel biomarkers within biologically enriched cancer patient population subsets. As such, all BTCRC studies will require annotated tissue acquisition, processing and storage. In addition, the consortium allows for the study of uncommon or rare tumors that might not otherwise be considered by the national cooperative groups.

Hoosier Oncology Group is uniquely positioned and equipped to fulfill the centralized management needs for the Big Ten Cancer Research Consortium. As administrative headquarters of the BTCRC, Hoosier Oncology continues to fulfill its mission of bringing the latest treatment options to patients within their community, guarantees a full pipeline of studies in development and provides Hoosier Oncology sustainable income for many years to come.

I look forward to the many challenges and opportunities the new consortium presents and am confident that Hoosier Oncology Group is the perfect fit to guarantee its success.

Best,

A handwritten signature in black ink that reads "Noah M. Hahn M.D." in a cursive script.



Our 2012 ASCO Showing

POSTER PRESENTATION

Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors: Hoosier Oncology Group GU09-145

T.E. Hutson; L.H. Dang; R.C. Lauer; A. Starodub; R.J. Hauke; M.D. Galsky; K.A. Bylow; T. Logan; C.L. Cowey; D.C. Bibby; G. Kremmidiotis; E.E. Doolin; T.C. Lavranos; G. Sonpavde; N.M. Hahn; C. Sweeney; J. Sarantopoulos.

POSTER PRESENTATION

Phase I/II study of a BNC105P/everolimus regimen for progressive metastatic renal cell carcinoma (mRCC) following prior tyrosine kinase inhibitors: Hoosier Oncology Group GU09-145

T.E. Hutson; L.H. Dang; R.C. Lauer; A. Starodub; R.J. Hauke; T. Logan; K.A. Bylow; M.D. Galsky; D.C. Bibby; G. Kremmidiotis; E.E. Doolin; T.C. Lavranos; A.F. Leske; N.M. Hahn; G. Sonpavde; C. Sweeney; J. Sarantopoulos.

POSTER ABSTRACT PRESENTATION

Phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122

N. Hahn; S. Daneshmand; E.M. Posadas; M.O. Koch; R. Bihrl; R. Foster; T.A. Masterson; L. Cheng; Z. Liu; T. Breen; M.T. Fleming; R. Lance; C.W. Ryan; C.L. Corless; M.D. Galsky; A.S. Alva; C. Mitchell; S.S. Shen; S.P. Lerner; G. Sonpavde.

TRIALS IN PROGRESS POSTER PRESENTATION

Phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for metastatic urothelial carcinoma: Hoosier Oncology Group GU10-148

B.A. Gartrell; N.M. Hahn; T.E. Hutson; G. Sonpavde; R.J. Hauke; A. Starodub; A.C. Small; C-K Tsao; M.D. Galsky.

ABSTRACT

Gene expression combined with gene set enrichment analysis to identify markers of vinorelbine efficacy in breast cancer patients: Hoosier Oncology Group COE05

R. Audet; C. Shen; S. Willis; R. Duchnowska; K. Adamowicz; J. Zok; W. Rogowski; M.M. Litwiniuk; S. Debska; M. Jaworska; M. Foszczynska-Kloda; M. Kulma-Kreft; K. Zabkowska; J. Jassem; S. Edgerton; A.D. Thor; K. Miller; G.W. Sledge; B. Leyland-Jones.

Our 2012 Peer-Reviewed Publications

Jordan M. Schmitt; Scott R. Sommers; William Fisher; Rafat Ansari; Erwin Robin; Karuna Koneru; John McClean; Ziyue Liu; Nasser Hanna:

Sunitinib plus paclitaxel in patients with advanced esophageal cancer: a phase II study from the Hoosier Oncology Group:

GI06-112 J Thorac Oncol; 2012; 7: 760-763



Awards and Advocacy





“...at the end I stepped to the side and saw the magnitude of the effort the gathering represented. Large and powerful as it was, ASCO was just the tip of the iceberg of the effort to push back on cancer. It provided a sharp contrast to the all alone feeling I had when I was diagnosed fourteen years ago.”

Tom Sibert

Husband, father, cancer survivor and Hoosier Oncology Group patient advocate


A Cancer Patient's Perspective on Research Today

Tom Sibert, a cancer survivor and Hoosier Oncology Group patient advocate, received an educational award funded by the Research Advocacy Network. The educational stipend afforded Tom the opportunity to attend the prestigious American Society of Clinical Oncology (ASCO) meeting.

The 2012 ASCO meeting, held in June in Chicago, IL, was attended by over 30,000 oncology community members representing all aspects of research, including medical professionals, drug companies, charitable organizations and government agencies. As part of the annual five-day meeting, oncology researchers exchange knowledge of the advances in cancer research through presentations, panel discussions and poster sessions.

During his ASCO experience, Tom gained much more knowledge about the biology of cancer and noted that many of the presentations focused on the molecular level of cancer cells. He learned that today, and in the future, oncologists will analyze an individual's tumor to identify biomarkers and use that information to develop individualized cancer treatments. Research still has a long road ahead, but with every cancer trial we gain more knowledge and are developing more effective treatments.

Many cancer patients may feel they are alone and powerless in their struggle, much as Tom did during his battle with non-Hodgkin's lymphoma. But the ASCO experience clearly convinced Tom that a cancer patient is not alone as they face their disease. There is a massive network of oncology researchers always fighting at their side.



A cancer patient is not alone as they face their disease.





“It is an honor to receive an award named for such an inspirational leader as Terry Hooppner. Working with the Hoosier Oncology Group, I try to help the organization contribute to the hope and never-give-up attitude that Coach Hooppner exemplified.”

Tom Sibert

*Terry Hooppner Patient
Advocacy Award Recipient*

Honoring the Dedication of Our Research Community

Terry Hooppner Patient Advocacy Award

Terry Hooppner, beloved Indiana University football coach, lost his battle with brain cancer in 2007. Coach Hep was known for his “never quit” attitude and determination to face challenges head-on. To honor his memory, his wife, Jane Hooppner, created the Terry Hooppner Patient Advocacy Award. Each year the award is given to an individual who embodies Coach Hep’s spirit and determination to champion their cause.

At the Clinical Trials Working Group meeting in July, Dr. Patrick Loehrer, Sr., presented the 2011 Terry Hooppner Patient Advocacy Award to Tom Sibert on behalf of Jane Hooppner. As a cancer survivor, Tom has dedicated much of his time to advancing cancer research through advocacy at the Hoosier Oncology Group. After his own battle with non-Hodgkin’s lymphoma, Tom volunteers on the Education Committee where he contributes a unique patient perspective in the development of patient education materials. In addition, Tom offers his talents as a motivational speaker at several meetings and events.

Hoosier Oncology Group is fortunate to have volunteers and advocates such as Tom working with us to develop the best possible treatments for cancer patients. Thank you, Tom!



Coach Hep was known for his “never quit” attitude and determination to face challenges head-on.





Honoring the Dedication of Our Research Community

The Sandra Turner Excellence in Clinical Research Awards

The Sandra Turner Excellence in Clinical Research Award was established in 2002 to honor the memory of Sandra Turner, the very first Executive Director of the Hoosier Oncology Group. Each year, the organization selects individuals who exemplify the qualities Sandra possessed and respected in others, such as sustained professional commitment, contribution to the progress of oncology care and the unflinching touch of compassion.

This year, two outstanding research professionals, Patricia Hurst, Nurse Coordinator at Community Regional Cancer Care, and Marietta Moore, Nurse Coordinator at Indiana University Melvin and Bren Simon Cancer Center, were selected as the 2012 recipients in recognition of their dedication and commitment to excellence in cancer research.

Patricia and Marietta each receive a \$1,500 unrestricted educational grant, generously provided by the Fisher Family Fund.

Congratulations to Patricia and Marietta. Thank you, and the rest of the research community, for your continued excellence in oncology research.

... in recognition of their dedication and commitment to excellence in cancer research.

“I was completely surprised and very honored to receive the Sandra Turner Award. I am excited to contemplate all the possible educational opportunities I can choose from. I am grateful to receive an award that honors such an outstanding individual. Thank you.”

Patricia Hurst, RN

*Community Regional Cancer Care
Sandra Turner Award Recipient*

“I feel honored and humbled to have received such a prestigious award. I have worked in many areas over the years of my nursing career and I have found oncology to be my favorite. I have made long term friendships with my patients and their family members and I love the fact that I am involved in multiple clinical trials that may enhance their lives and lead to new treatments for patients all over the world. I truly thank the Hoosier Oncology Group for selecting me for this award.”

Marietta Moore, RN

*Indiana University Melvin and Bren Simon Cancer Center
Sandra Turner Award Recipient*





“I was honored to be selected as the recipient of the 2012 George and Sarah Jane Fisher Young Investigator Award. Working with [Hoosier Oncology Group] was a very rewarding experience. I had the opportunity to work with great researchers and to start my first clinical trial.”

Costantine Albany, M.D.,

George and Sarah Jane Fisher Young Investigator Award Recipient

Funding the best and brightest researchers

George and Sarah Jane Fisher Young Investigator Award


In 2011, Dr. William B. Fisher generously endowed a new award through the Fisher Family Fund to challenge the next generation of cancer researchers. The George and Sarah Jane Fisher Young Investigator Award will be given annually to the Indiana University oncology fellow deemed to have made the most significant contribution to clinical or basic science research in collaboration with the Hoosier Oncology Group.

In recognition of his work with the testis cancer research program, Costantine Albany, M.D., GU Oncology Fellow at Indiana University School of Medicine, was selected to receive this inaugural award, along with a \$5,000 unrestricted grant to fund future research projects.

Coach Hep Indiana Cancer Challenge

The Coach Hep Indiana Cancer Challenge (CHICC) organization was established in memory of nationally-known IU Football Coach Terry Hoepfner (“Coach Hep”) who faced every obstacle, even brain cancer, with a positive, “Don’t Quit” attitude and determined optimism. CHICC honors the accomplishments and commitment of extraordinary individuals who display those qualities in the fight against cancer.

After evaluating numerous submissions from highly-qualified candidates, Hoosier Oncology Group selected Dr. Shadia Jalal’s application, “The Role of Homology-Directed Repair in Genomic Instability and Metastases in Non-Small Cell Lung Cancer (NSCLC)”. Her research project will analyze tissue obtained from lung cancer patients with adenocarcinoma, which was collected through a Hoosier Oncology Group biological sample collection protocol (BNK09-138). Dr. Jalal holds the faculty position of Assistant Professor of Medicine at IU School of Medicine and is an active clinical team member of the Thoracic Oncology Program at IU Simon Cancer Center.



Financials





Report of Independent Auditors

Crowe Horwath LLP



Crowe Horwath LLP
Independent Member Crowe Horwath International

We have audited the accompanying statements of financial position of the Hoosier Oncology Group, Inc. (the "Organization") as of June 30, 2012 and 2011 and the related statements of activities and cash flows for the years then ended. These financial statements are the responsibility of the Organization's management. Our responsibility is to express an opinion on these financial statements based on our audits.

We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Hoosier Oncology Group, Inc. as of June 30, 2012 and 2011, and the changes in its net assets and its cash flows for the years then ended in conformity with accounting principles generally accepted in the United States of America.

Our audits were conducted for the purpose of forming an opinion on the financial statements as a whole. The supplemental schedules of functional expenses are presented for purposes of additional analysis and are not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audits of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the information is fairly stated in all material respects in relation to the financial statements as a whole.

Crowe Horwath LLP

Crowe Horwath LLP
Indianapolis, Indiana
November 27, 2012



HOOSIER ONCOLOGY GROUP, INC.
STATEMENTS OF FINANCIAL POSITION
June 30, 2012 and 2011

	<u>2012</u>	<u>2011</u>
ASSETS		
Cash and cash equivalents	\$ 2,374,582	\$ 2,367,266
Accounts and grants receivable, net	1,872,855	1,158,635
Prepaid expenses	146,972	77,407
Property and equipment, net (Note 2)	<u>25,435</u>	<u>34,471</u>
Total assets	<u>\$ 4,419,844</u>	<u>\$ 3,637,779</u>
 LIABILITIES AND NET ASSETS		
Liabilities		
Accounts payable	\$ 286,142	\$ 139,609
Affiliate sites payable (Note 1)	272,463	244,952
Accrued payroll and vacation	64,836	80,626
Total liabilities	<u>623,441</u>	<u>465,187</u>
Net assets		
Unrestricted	3,628,785	2,989,974
Temporarily restricted (Note 1)	<u>167,618</u>	<u>182,618</u>
Total net assets	<u>3,796,403</u>	<u>3,172,592</u>
Total liabilities and net assets	<u>\$ 4,419,844</u>	<u>\$ 3,637,779</u>

The full version of the audited financial statements including note disclosures is available upon request.



HOOSIER ONCOLOGY GROUP, INC.
STATEMENTS OF ACTIVITIES

Year ended June 30, 2012 (with summary total for the year ended June 30, 2011)

	<u>Unrestricted</u>	<u>Temporarily Restricted</u>	<u>2012 Total</u>	<u>2011 Total</u>
Revenues				
External support - research	\$ 3,790,014	\$ -	\$ 3,790,014	\$ 2,393,380
Federal research grants	133,993	-	133,993	345,206
Contributions and other grant support	381,636	-	381,636	578,345
Interest income	7,542	-	7,542	7,411
Other income	4,592	-	4,592	18,815
Release from restriction	15,000	(15,000)	-	-
Total revenues	4,332,777	(15,000)	4,317,777	3,343,157
Expenses				
Program services				
Investigator initiated research	1,475,096	-	1,475,095	1,772,681
Industry research	1,275,466	-	1,275,466	430,907
Government research	275,702	-	275,702	588,989
Total program services	3,026,264	-	3,026,263	2,792,577
Supporting services				
Administration	660,564	-	660,564	638,548
Fundraising	7,138	-	7,138	21,173
Total supporting services	667,702	-	667,702	659,721
Total expenses	3,693,966	-	3,693,966	3,452,298
Change in net assets	638,811	(15,000)	623,811	(109,141)
Net assets, beginning of year	2,989,974	182,618	3,172,592	3,281,733
Net assets, end of year	\$ 3,628,785	\$ 167,618	\$ 3,796,403	\$ 3,172,592



HOOSIER ONCOLOGY GROUP, INC.
STATEMENTS OF CASH FLOW
 Years ended June 30, 2012 and 2011

	<u>2012</u>	<u>2011</u>
Cash flows from operating activities		
Change in net assets	\$ 623,811	\$ (109,141)
Adjustments to reconcile change in net assets to net cash from operating activities:		
Depreciation	11,766	12,444
Change in assets and liabilities:		
Accounts and grants receivable	(714,220)	319,534
Prepaid expenses	(69,565)	(6,299)
Accounts payable	146,533	(69,482)
Affiliate sites payable	27,511	14,804
Accrued payroll and vacation	(15,790)	28,698
Deferred revenue	-	(23,599)
Net cash from operating activities	10,046	166,959
Cash flows from investing activities		
Purchase of property and equipment	(2,730)	(22,322)
Net cash from investing activities	(2,730)	(22,322)
Net change in cash and cash equivalents	7,316	144,637
Cash and cash equivalents at beginning of year	2,367,266	2,222,629
Cash and cash equivalents at end of year	\$ 2,374,582	\$ 2,367,266





Our Contributors



The Hoosier Oncology Group wishes to thank all those who contributed throughout the year to our mission of providing leading research to people within their communities.

We are so fortunate to have many friends and supporters who give of their time, treasure, expertise and other valuable resources to help us fulfill our mission.

The Hoosier Oncology Group also wishes to thank all the dedicated investigators, clinical research site personnel, volunteers and the patients who make our research possible.

We would like to gratefully acknowledge:

Janie Gordon for her generosity of time and talent

Board member Ted Stansbury for his leadership in donor relations and community outreach

Coach Hep Indiana Cancer Challenge

*The Hoosier Oncology Group strives to acknowledge each and every contributor accurately. The information above reflects contributions made between July 1, 2011 – June 30, 2012. If the information listed above is incorrect or not inclusive, please contact our offices at 317-921-2050 and ask to speak with donor relations. Thank you for your support!

Our Contributors*

PLATINUM LEVEL (\$5000 and above)

Jane Hoepfner

Coach Hep Indiana Cancer Challenge

SILVER LEVEL (\$800-\$2499)

Rafat Abonour, Board Member

In Honor of Patrick Loehrer

North Columbus

In Honor of Janie Gordon

Tracey Day

In Honor of Dave Tyndall

William Fisher

Mary Lou Mayer

Ted Stansbury, Board Member

In Memory of John H. Waffle

In Memory of Bob Thorne

BRONZE LEVEL (\$250-\$799)

Suzanne Austin

In Memory of John H. Waffle

Mark Drysdale

In Memory of John H. Waffle

Christopher Fausel

In Memory of Stephen D. Williams, M.D.

Noah Hahn, Board Member

Nasser Hanna, Board Member

Kevina Schumaker

FRIENDS (\$249 and under)

Monica Anderson

In Memory of John H. Waffle

Matthew Caito

In Memory of Pat Rawle

Wael Harb

In Memory of John H. Waffle

Shelly Huck

In Memory of John H. Waffle

Jason Pletcher

Chris LeMasters, Board Member

Pam Livingston

In Memory of John H. Waffle

Florence Mikle

In Memory of John H. Waffle

Edward Miller

Dawn Teetzel

In Memory of John H. Waffle

Jay Turpen

In Memory of John H. Waffle

Pauline Waffle

In Memory of John Drysdale

Robert Waffle

In Memory of John H. Waffle

Mary Jean Wasielewski

In Memory of John H. Waffle





hoosier oncology group

leading cancer research, close to home

351 W. 10th Street, Suite 330 | Indianapolis, IN 46202

P 317 921 2050

www.hoosieroncologygroup.org